Laboratoires Vivacy
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Dec 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 13, 2027The maintenance fee for Methods and kits for treating vaginal and vulvar vestibule mucosa disorders (US 9,155,757) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups (US 9,175,097) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Composition, in aqueous medium, that comprises at least a hyaluronic acid and at least an hydrosoluble salt of sucrose octasulfate (US 9,314,530) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,919,076 | Biodegradable Single-Phase Cohesive Hydrogels In force · Medium confidence | In force | Medium confidence | |
| US 10,207,024 | Biodegradable Single-Phase Cohesive Hydrogels In force · Medium confidence | In force | Medium confidence | |
| US 9,175,097 | Process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups In force · From the USPTO record | In force | From the USPTO record | |
| US 10,058,499 | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate In force · From the USPTO record | In force | From the USPTO record | |
| US 9,155,757 | Methods and kits for treating vaginal and vulvar vestibule mucosa disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,314,530 | Composition, in aqueous medium, that comprises at least a hyaluronic acid and at least an hydrosoluble salt of sucrose octasulfate In force · From the USPTO record | In force | From the USPTO record | |
| US 9,402,799 | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate In force · From the USPTO record | In force | From the USPTO record | |
| US D870,272 | Hypodermic syringe In force · From the USPTO record | In force | From the USPTO record | |
| US D870,273 | Hypodermic syringe In force · From the USPTO record | In force | From the USPTO record | |
| US 10,004,824 | Compositions comprising at least one polyol and at least one anesthetic In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 2 abandoned · 4 no status recorded